Trial Profile
A phase I dose escalation study of intravesical TMX-101 in subjects with Non-Muscle-Invasive Bladder Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 26 Aug 2013
Price :
$35
*
At a glance
- Drugs Imiquimod (Primary)
- Indications Bladder cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Telormedix
- 26 Aug 2013 New source identified and integrated (ISRCTN: Current Controlled Trials)
- 21 Aug 2013 Status changed from recruiting to completed, according to ISRCTN: Current Controlled Trials
- 10 Jan 2012 Telormedix received CHF7.5 million in financing, which in part, will be used to support this trial, according to a company media release.